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Introduction {#sec1}
============

Lipid membranes deform for fission and fusion during various cellular events, including endocytosis, vesicle transport, and organelle division ([@bib17], [@bib33], [@bib41], [@bib42]). The proteins involved in membrane scission include dynamin, endosomal sorting complexes required for transport (ESCRT), and several proteins containing amphipathic helices, such as endophilin, Epsin, Arf1, and Sar1p ([@bib3], [@bib25], [@bib31], [@bib40], [@bib58]). Bin-Amphiphysin-Rvs167 (BAR) domains form a curved structure and deform membranes to tubules through electrostatic interactions between the negatively charged lipids and positively charged surface of the BAR domain ([@bib6], [@bib51]). Some BAR domains, including those of endophilin, contain amphipathic helices involved in membrane scission and tubulation ([@bib3], [@bib30], [@bib39]). Owing to the variety of intracellular membrane vesicles, proteins necessary for membrane scission are not considered to be fully identified.

We previously reported that the ankyrin-repeat domain (ARD) of the transient receptor potential cation channel subfamily V member 4 binds to lipids, including phosphatidylinositol (4,5) bisphosphate ([@bib52]). *Arabidopsis* ankyrin repeat protein 2A (AKR2A) contains an ARD that binds to monogalactosyldiacylglycerol and phosphatidylglycerol ([@bib21]), implying the potential existence of uncharacterized ARDs with lipid-binding ability. *Homo sapiens* have approximately 600 ARD-containing proteins ([@bib27]). However, the lipid-binding and lipid-deforming abilities of most ARDs have not been investigated.

ARDs comprise several tandemly aligned ankyrin repeats (ANKs). ANK contains two antiparallel α-helices ([@bib28]). The number of ANKs varies among ARDs ([@bib34]). The variation in ANK number results in a variety of protein surfaces, which often adopt curved structures. These properties imply that ARDs function as scaffolds for membrane deformation, similar to BAR domains.

In this study, we analyzed the membrane-binding and vesiculation abilities of 18 highly transcribed ARDs through a liposome sedimentation assay. We determined the membrane vesiculation potential of ANKHD1 and investigated its function in early endosomes.

Results {#sec2}
=======

Identification of Membrane Vesiculation of ANKHD1 ARD {#sec2.1}
-----------------------------------------------------

We expected highly transcribed genes to be essential for cellular functions. Among the approximately 600 proteins with ARDs in *Homo sapiens* ([@bib27]), we selected 18 based on the high frequencies of expressed sequence tags (ESTs) in the Unigene database ([@bib1]) ([Figure S1](#mmc1){ref-type="supplementary-material"}).

These 18 ARDs were expressed in *Escherichia coli* and purified ([Figure 1](#fig1){ref-type="fig"}A). Binding of each ARD to liposomes and subsequent liposome vesiculation were examined via a liposome sedimentation assay. Co-sedimentation of an ARD with liposomes indicated the binding of that ARD to liposomes. The sedimentation efficiency depends on liposome size, and decreased liposome sedimentation occurs with a reduction in liposome size in the presence of proteins. This reduction in liposome sedimentation reflects the vesiculation ability of the protein ([@bib3]). The number of liposomes in the supernatant and in the pellet was determined by incorporating rhodamine-labeled phosphatidylethanolamine (PE) into liposomes ([Figure 1](#fig1){ref-type="fig"}B).Figure 1Identification of ANKHD1 ARD as a Membrane Vesiculation Protein(A) The 18 purified ARD fragments. The purity of these proteins was examined by SDS-PAGE with Coomassie brilliant blue staining (CBB). See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"}.(B) Illustration of vesiculation by liposome sedimentation assay. When the liposomes were labeled with a small amount of fluorescent-labeled lipids such as rhodamine-PE, the small vesiculated liposomes were not effectively pelleted, which increased the fluorescence from labeled lipids in the supernatant.(C--G) Percentage of rhodamine-PE in the supernatants in liposome sedimentation assay. Liposomes containing PC, PE, PS, and rhodamine-PE prepared at a weight ratio of 6:3:1:0.02 were incubated with the 18 proteins containing ARD fragments (1 μM) for 30 min and then subjected to ultracentrifugation at 109,000 × *g*. The supernatant (S) and the pellet (P) fractions were analyzed by SDS-PAGE, followed by visualization of the protein by CBB staining and the liposomes by rhodamine fluorescence. The percentages of rhodamine-PE in the supernatant are shown as the mean of three independent experiments. (C) ASAP1 443-737 aa and OSTF1 1-215 aa. (D) ACAP2 581-770 aa, CLPB 86-330 aa, EHMT1 684-1008 aa, EHMT2 628-968 aa, PPP1R12B 1-358 aa, and FEM1A 1-654 aa. (E) ANKHD1 195-1418 aa, ANKFY1 213-1169 aa, KANK1 1069-1360 aa, PPP1R12C 1-345 aa, RFXANK 1-259 aa, and CDKN2C 1-168 aa. (F) CDKN2D 1-166 aa, ANKRD11 140-297 aa, and ANKRD12 161-311 aa. (G) ANKRD17 224-1410 aa.(H) Vesiculation by liposome sedimentation assay for ARD25 at 1 μM and 250 nM. The lipid compositions of the liposomes were PC:PE:PS:rhodamine-PE at a weight ratio of 6:3:1:0.02 and porcine brain lipids:rhodamine-PE at a weight ratio of 10:0.02.(I) Quantification of liposomes in (H). Data represent the mean of three (250 nM protein) and four (1 μM protein) independent experiments.(J and K) Electron micrographs of liposomes of PC:PE:PS at a weight ratio of 6:3:1 (J) and porcine brain lipids (K) after incubation with ARD25 (1 μM) for 20 min. Liposomes were visualized by negative staining. The boxed region presents an enlarged image. Scale bars, 100 nm.All error bars represent SE. \*p \< 0.05, \*\*p \< 0.01. Statistical significance value was determined using the Student\'s t test.

We prepared liposomes containing phosphatidylcholine (PC), PE, and phosphatidylserine (PS) at a weight ratio of 6:3:1 because PC and PE are abundant, whereas PS is not abundant in intracellular organelles, including endosomes, the Golgi complex, endoplasmic reticulum (ER), and mitochondria ([@bib7], [@bib15], [@bib19], [@bib29], [@bib54]). We then incubated each of the 18 protein fragments with protein-free liposomes ([Figures 1](#fig1){ref-type="fig"}C--1G). Among the 18 protein fragments, the ARD of ANKHD1, containing 25 ANKs (ANKHD1 195--1418 amino acid residues, also termed ARD25), had the highest membrane vesiculation activity ([Figure 1](#fig1){ref-type="fig"}E). ANK and FYVE domain-containing 1 (ANKFY1) displayed weaker membrane vesiculation ability than ANKHD1 ([Figure 1](#fig1){ref-type="fig"}E). Ankyrin repeat domain-containing protein 17 (ANKRD17), a paralog of ANKHD1, displayed membrane vesiculation ability ([Figure 1](#fig1){ref-type="fig"}G).

To determine the presence of a group of ARDs with membrane-deforming abilities, ANKs of all ARDs were examined for sequence similarities in *Homo sapiens*. The amino acid sequences between the ANKs of ANKHD1 and ANKRD17 are conserved, forming a distinct group among the 18 highly transcribed ARD-containing proteins ([Figure S2](#mmc1){ref-type="supplementary-material"}). However, among all human proteins containing ARDs, the ANKs of ANKHD1 are not grouped by amino acid sequence similarity ([Figure S3](#mmc1){ref-type="supplementary-material"}), suggesting the importance of ARD as an assembly of several ANKs for their function. The average EST frequency for ANKHD1 was 167 transcripts per million (TPM), which was the highest among the 18 proteins ([Figure S1](#mmc1){ref-type="supplementary-material"}B). The ANKHD1 EST frequency was equivalent to those of SH3GL1 (endophilin A2, 100 TPM) and ACTR3 (Arp3, 234 TPM). Endophilin A2 is a protein containing a BAR domain. ACTR3 is a component of the abundant Arp2/3 protein complex, which induces branched actin filaments. Therefore, we focused on ANKHD1 in subsequent studies.

To examine whether the ARD of ANKHD1 vesiculates liposomes constituted with natural lipids, we examined the vesiculation of liposomes constituted with total lipids (Folch fraction) from porcine brain using the liposome sedimentation assay. ARD25 at 1 μM vesiculated the Folch fraction liposomes ([Figures 1](#fig1){ref-type="fig"}H and 1I). At 250 nM, ARD25 protein did not vesiculate liposomes constituted with porcine brain lipids or of PC:PE:PS at a weight ratio of 6:3:1 ([Figures 1](#fig1){ref-type="fig"}H and 1I). To confirm liposome vesiculation by ARD25, we observed liposomes after incubation with ARD25 via transmission electron microscopy. Consistent with the sedimentation assay, the liposomes of PC/PE/PS and the Folch fraction were vesiculated into small vesicles in the presence of ARD25 at 1 μM ([Figures 1](#fig1){ref-type="fig"}J and 1K). These results suggest that ANKHD1 can vesiculate liposomes constituted with natural lipids depending on the protein concentration.

Increased Total Area of EEA1-Positive Early Endosomes and Decreased Total Area of Mitochondria in ANKHD1-Depleted Cells {#sec2.2}
-----------------------------------------------------------------------------------------------------------------------

To investigate the cellular function of ANKHD1, ANKHD1 was depleted from HeLa cells, using small interfering RNA (siRNA). Western blot was performed to quantify marker proteins of intracellular organelles: EEA1 for early endosomes ([@bib62]), GM130 for *cis*-Golgi ([@bib37]), Calnexin for ER ([@bib56]), and Bcl-2 for mitochondria ([@bib59]). Western blots were carried out with lysates of cells treated with control siRNA and ANKHD1 siRNA ([Figures 2](#fig2){ref-type="fig"}A and 2B). The reduction in ANKHD1 was associated with the upregulation of EEA1, GM130, and Calnexin and downregulation of Bcl-2 ([Figures 2](#fig2){ref-type="fig"}A and 2B). A similar EEA1 upregulation was observed in other ANKHD1-depleted cells, including HEK293T, Caki-1, U2OS, and DLD1 cells ([Figure S4](#mmc1){ref-type="supplementary-material"}A).Figure 2Quantity of Organelle Marker Proteins in ANKHD1-Depleted Cells(A) Effect of ANKHD1 knockdown on the levels of various organelle marker proteins. HeLa cells were treated with control or ANKHD1 siRNA. The whole-cell lysates were subjected to western blot with antibodies for early endosome (EEA1), *cis*-Golgi (GM130), ER(Calnexin), and Bcl-2 (mitochondria). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was examined as the loading control. See also [Figures S4](#mmc1){ref-type="supplementary-material"}A, [S6](#mmc1){ref-type="supplementary-material"}A, and S6B.(B) Quantification of the signal intensities in (A) using ImageJ software. Data represent the mean of five independent experiments.(C) Confocal microscopic analysis of EEA1 in HeLa cells treated with control or ANKHD1 siRNA by immunostaining. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.(D and E) The total area (D) and the number (E) of EEA1 puncta per cell in (C) were measured by ImageJ software. Data represent the mean of 43 and 42 cells from three independent experiments for control siRNA and ANKHD1 siRNA, respectively. See also [Figures S6](#mmc1){ref-type="supplementary-material"}C--S6H and [S8](#mmc1){ref-type="supplementary-material"}.(F) Confocal microscopic analysis of GM130 as in (C).(G and H) The total area (G) of GM130 staining per cell in (F) measured as in (D) and the number of Golgi fragments (H) per cell in (F) are shown. Data represent the mean of 68 and 78 cells from three independent experiments for control siRNA and ANKHD1 siRNA, respectively.(I) Confocal microscopic analysis of Calnexin as in (C).(J) The total area of Calnexin staining per cell in (I) was measured as in (D). Data represent the mean of 44 and 46 cells from three independent experiments for control siRNA and ANKHD1 siRNA, respectively.(K) Confocal microscopic analysis of mitochondria stained with MitoTracker as in (C).(L) The total area of MitoTracker staining per cell in (K) was measured as in (D). Data represent the mean of 55 and 52 cells from three independent experiments for control siRNA and ANKHD1 siRNA, respectively.All error bars represent SE. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001. Statistical significance was determined with the Student\'s t test. ns, not significant. Scale bars, 10 μm.

Thereafter, we measured the quantity of these organelles in control siRNA and ANKHD1-siRNA-treated cells ([Figures 2](#fig2){ref-type="fig"}C--2L). The total area and the number of EEA1 puncta were higher in ANKHD1-siRNA-treated cells than in the control cells at each focal plane upon confocal microscopy ([Figure S5](#mmc1){ref-type="supplementary-material"}). Therefore, we used the focal plane adjacent to the surface of cellular attachment on the coverslips, where the area of cells is the largest, to quantify the changes in organelles. The total area of EEA1 localization and the number of EEA1 puncta per cell increased approximately by 1.5-fold in ANKHD1 siRNA-treated cells relative to that in the control siRNA-treated cells ([Figures 2](#fig2){ref-type="fig"}C--2E), suggesting an increase of the EEA1-positive early endosomes upon depletion of ANKHD1. Interestingly, the total mitochondrial area of the ANKHD1-siRNA-treated cells was approximately 70% of the control siRNA-treated cells, as examined via MitoTracker staining ([Figures 2](#fig2){ref-type="fig"}K and 2L). In contrast, the total area and number of Golgi fragments stained with GM130 remained unchanged upon ANKHD1 siRNA treatment ([Figures 2](#fig2){ref-type="fig"}F--2H). In addition, the total area of Calnexin localization remained unchanged ([Figures 2](#fig2){ref-type="fig"}I and 2J). Hence, ANKHD1 knockdown was associated with an increase in the total area of EEA1-positive early endosomes and a reduction in the total area of mitochondria. As ANKHD1 vesiculates the membrane, the siRNA for ANKHD1 was considered to increase the area of organelles that was vesiculated by ANKHD1. Therefore the EEA1-localized early endosomes, not mitochondria, are potential sites of ANKHD1 activity.

EEA1 is the tethering factor of early endosomes for membrane fusion of endocytic vesicles with the small GTPase Rab5 ([@bib35]) and can thus be used to identify mature early endosomes, whereas Rab5 is localized to early endosomes and endocytic vesicles regardless of early endosome maturation ([@bib9], [@bib14], [@bib62]). The level of endogenous Rab5 remained unchanged upon treatment with ANKHD1 siRNA ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). Interestingly, the total area of endogenous Rab5 localization was not significantly altered upon treatment with ANKHD1 siRNA ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D). However, the number of the endogenous Rab5 puncta decreased upon treatment of ANKHD1 siRNA, where the average area of Rab5 puncta was increased by the decrease in the smaller Rab5 puncta ([Figures S6](#mmc1){ref-type="supplementary-material"}E--S6G). The colocalization of Rab5 with EEA1 was increased in the ANKHD1-depleted cells ([Figure S6](#mmc1){ref-type="supplementary-material"}H), where most of the EEA1-positive puncta contained Rab5. Therefore, these data suggest the increase of EEA1-Rab5-double-positive early endosome upon depletion of ANKHD1. Thus an increase in the number of EEA1 puncta indicates an increase of the EEA1-positive early endosomes by the inhibition of the ANKHD1-mediated vesiculation, which would further inhibit the subsequent trafficking of the vesiculated early endosomes.

Subcellular Localization of ANKHD1 {#sec2.3}
----------------------------------

To examine the localization of endogenous ANKHD1, we stained endogenous ANKHD1 and EEA1 with anti-ANKHD1 and anti-EEA1 antibodies, respectively ([Figures 3](#fig3){ref-type="fig"}A and 3B). Partial colocalization of these two proteins was observed. Similar to HeLa cells, partial colocalization of ANKHD1 with EEA1 was observed in HEK293T, Caki-1, U2OS, and DLD1 cells ([Figure S4](#mmc1){ref-type="supplementary-material"}B). In HeLa cells, the colocalization of ANKHD1 with EEA1 was confirmed using ANKHD1-tagged with enhanced green fluorescent protein (EGFP) ([Figure 3](#fig3){ref-type="fig"}C).Figure 3Localization of ANKHD1 on Endosomes(A) Confocal microscopic images of endogenous ANKHD1 (green) and EEA1 (red) in HeLa cells. The rectangle in the upper image shows the region of enlargement in the lower images. Arrows indicate colocalization of endogenous ANKHD1 and EEA1. See also [Figure S4](#mmc1){ref-type="supplementary-material"}B.(B) Colocalization percentages of endogenous ANKHD1 with EEA1 and EEA1 per cell in (A) calculated using ImageJ software. Data represent the means of nine cells.(C) Confocal microscopic images of ANKHD1-EGFP (green) and EEA1 (red) in HeLa cells. Arrows indicate colocalization of ANKHD1-EGFP and EEA1.(D and E) Confocal microscopic images of the endogenous ANKHD1 (green) in HeLa cells overexpressing (D) mCherry-Rab5 or (E) mCherry-Rab5Q79L, shown in red.(F) Colocalization percentages of endogenous ANKHD1 with mCherry-Rab5 or mCherry-Rab5Q79L and mCherry-Rab5 or mCherry-Rab5Q79L per cell in (D and E). Data represent the mean of 10 and 11 cells overexpressing mCherry-Rab5 and mCherry-Rab5Q79L, respectively. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.All error bars represent SE. \*p \< 0.05. Statistical significance was assessed with the Student\'s t test. ns, not significant. Scale bars, 10 μm. Scale bars in magnification, 2 μm.

To further characterize the localization of ANKHD1 in endosomes, we examined the colocalization of ANKHD1 and Rab5, because active Rab5 recruits EEA1 to early endosomes ([@bib23]). When we examined the colocalization of the two proteins above the threshold level, endogenous ANKHD1 was partially colocalized with mCherry-tagged Rab5, the constitutive active Q79L mutant of Rab5, and endogenous Rab5 ([Figures 3](#fig3){ref-type="fig"}D--3F, [S7](#mmc1){ref-type="supplementary-material"}A, and S7F). Therefore, ANKHD1 was considered to be recruited by active Rab5 on early endosomes. In particular, the large early endosomes containing Rab5Q79L also contained ANKHD1 ([Figure 3](#fig3){ref-type="fig"}E). The late endosomes/lysosomes and mitochondria were visualized using anti-LAMP1 and anti-Tom20 antibodies, respectively ([@bib18], [@bib44]), in addition to Rab5 for early endosomes, GM130 for *cis*-Golgi, and Calnexin for the ER. Colocalization of endogenous ANKHD1 with Rab5 and Tom20 was greater than that with LAMP1, GM130, and Calnexin ([Figure S7](#mmc1){ref-type="supplementary-material"}).

ANKHD1 Antagonizes Rab5-Induced Enlargement of Early Endosomes {#sec2.4}
--------------------------------------------------------------

We then examined the effect of ANKHD1 depletion in Rab5-positive early endosomes. Interestingly, ANKHD1 knockdown did not change the number of GFP-tagged Rab5-positive early endosomes, but decreased the number of Rab5Q79L-positive early endosomes ([Figures 4](#fig4){ref-type="fig"}A, 4B, 4D, and 4E). However, the average area of these GFP-Rab5 and Rab5Q79L-positive early endosomes was increased in the ANKHD1 siRNA-treated cells ([Figures 4](#fig4){ref-type="fig"}A, 4C, 4D, and 4F), and the small Rab5Q79L puncta were almost absent in ANKHD1 siRNA-treated cells. We then examined ANKHD1 localization in early endosomes without fixation, using mCherry-tagged Rab5 and Rab5Q79L as an early endosomal marker. To better visualize the localization of expressed ANKHD1, three Venus tags ([@bib36]) were tandemly conjugated and used to tag ANKHD1. In ANKHD1-depleted cells weakly expressing ANKHD1-Venus×3 and mCherry-Rab5 or mCherry-Rab5Q79L, ANKHD1 transiently colocalized with Rab5 and Rab5Q79L upon scission of mCherry-Rab5 and mCherrry-Rab5Q79L puncta ([Figures 4](#fig4){ref-type="fig"}G and 4H and [Video S1](#mmc2){ref-type="supplementary-material"}).Figure 4ANKHD1 Regulates Rab5-Positive Organelles and Recruitment at the Scission Site(A) Confocal microscopic images of overexpressed EGFP-Rab5 in HeLa cells treated with control siRNA or ANKHD1 siRNA. Scale bars, 10 μm.(B and C) Quantification of the number (B) and average area (C) of EGFP-Rab5 puncta per cell in (A). Data represent the mean of 21 and 18 cells from three independent experiments for control siRNA and ANKHD1 siRNA, respectively.(D) Confocal microscopic images of overexpressed EGFP-Rab5Q79L in HeLa cells treated with control siRNA or ANKHD1 siRNA. Scale bars, 10 μm.(E and F) Quantification of the number (E) and the average area (F) of EGFP-Rab5Q79L puncta per cell in (D). Data represent the mean of 30 and 29 cells from three independent experiments for control siRNA and ANKHD1 siRNA, respectively.(G) Live imaging of HeLa cells co-transfected with ANKHD1 siRNA, ANKHD1-Venus×3, and mCherry-Rab5. Arrows indicate early endosome scission. Scale bar, 1 μm.(H) Live imaging of HeLa cells co-transfected with ANKHD1 siRNA, ANKHD1-Venus×3, and mCherry-Rab5Q79L. Arrows indicate early endosome scission. Scale bar, 1 μm.(I) Proposed function of ANKHD1. ANKHD1 is recruited to Rab5-positive early endosomes for membrane vesiculation.All error bars represent SE. \*p \< 0.05 and \*\*\*p \< 0.001. Statistical significance was determined with the Student\'s t test. ns, not significant.

Video S1. Video Corresponding to the Image in Figure 4H, Related to Figure 4The frame interval of the images is 1.24 s.

The switch from Rab5 to Rab7 is important for the maturation of early endosomes to late endosomes and lysosomes. Endosome maturation is accompanied by the acidification of the lumen and is detected via LysoTracker staining ([@bib16], [@bib43]). The number, average area, and total area of lysosomes remained unchanged in cells treated with control or ANKHD1 siRNA ([Figure S8](#mmc1){ref-type="supplementary-material"}). As early endosomes are enlarged upon fusion of endocytic vesicles, these data suggested that the vesiculation ability of ANKHD1 antagonized the enlargement of early endosomes with active Rab5 localization without affecting endosome maturation ([Figure 4](#fig4){ref-type="fig"}I).

The Regions of ANKHD1 for Membrane Vesiculation and Dimerization {#sec2.5}
----------------------------------------------------------------

To examine the mechanism underlying ANKHD1 for membrane vesiculation, the predicted structured (ordered) region of the ANKHD1 was assessed using a disorder-prediction program ([@bib57]). Although the KH domain was assigned on the basis of sequence homology, the region outside of the ARD was mostly disordered ([Figure 5](#fig5){ref-type="fig"}A). We prepared several ANKHD1 fragments. N + ARD25 contains 1--1587 amino acids (aa) of ANKHD1, including the N-terminal region and an additional 169 aa of the ARD25 C-terminal region. N + ARD15 and ARD10 contain 1--885 aa and 886--1587 aa of ANKHD1, which contain the group of 15 ANKs and the group of 10 ANKs, respectively ([Figure 5](#fig5){ref-type="fig"}A).Figure 5Dimerization and Vesiculation Ability of ANKHD1(A) Illustration of human ANKHD1 and the fragments: ANKHD1 (1--2542 aa), N + ARD15 (ANKHD1 1--885 aa), ARD10 (ANKHD1 886--1587 aa), N + ARD25 (ANKHD1 1--1587 aa), and ARD25 (ANKHD1 195--1418 aa). ANK, amphipathic helix, and the KH domain were indicated. Disorder probability was also plotted by PrDOS (<http://prdos.hgc.jp>).(B) Level of expressed ANKHD1 fragments, endogenous EEA1, and endogenous ANKHD1 in ANKHD1-depleted HeLa cells expressing EGFP, N + ARD15-EGFP, ARD10-EGFP, N + ARD25-EGFP, ARD25-EGFP, or ANKHD1-EGFP for rescue experiments by western blot. See also [Figure S9](#mmc1){ref-type="supplementary-material"}.(C) Quantification of EEA1 in (B). Data represent the mean of three independent experiments.(D) Vesiculation by liposome sedimentation assay for N + ARD15, ARD10, N + ARD25, and ARD25 at 250 nM using ultracentrifugation at 109,000 × *g*. The lipid composition of the liposomes was PC:PE:PS:rhodamine-PE at weight ratio of 6:3:1:0.02.(E) Quantification of liposomes in (D). Data represent the mean of three independent experiments.(F) Electron micrographs of liposomes of PC:PE:PS at a weight ratio of 6:3:1 after incubation with N + ARD15, ARD10, N + ARD25, or ARD25 at 250 nM for 20 min. Liposomes were visualized by negative staining. The boxed region presents an enlarged image. Scale bars, 100 nm.(G) Vesiculation by liposome sedimentation assay for N + ARD15 and ARD10 at 1 μM using ultracentrifugation at 109,000 × *g*. The lipid composition of the liposomes was PC:PE:PS:rhodamine-PE at weight ratio of 6:3:1:0.02.(H) Quantification of liposomes in (G). Data represent the mean of three independent experiments.(I) Cross-linking assay for ANKHD1 fragments. N + ARD15, ARD10, N + ARD25, or ARD25 at 250 nM were incubated with or without liposome composed of PC:PE:PS at a weight ratio of 6:3:1 and then incubated with BS(PEG)5 at a final concentration of 100 μM. The box indicates the dimer formation of ANKHD1 fragments.All error bars represent SE. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001. Statistical significance was determined with the Student\'s t test. ns, not significant.

When these ANKHD1 fragments and ANKHD1 were expressed in HeLa cells depleted of ANKHD1 via siRNA, N + ARD15, N + ARD25, and ARD25 expression levels were equivalent, although the exogenous ANKHD1 expression levels were lower than those of these fragments, and ARD10 expression levels were very low ([Figure 5](#fig5){ref-type="fig"}B). ANKHD1 and N + ARD25 downregulated EEA1 in ANKHD1-depleted cells ([Figures 5](#fig5){ref-type="fig"}B and 5C); however, expression of the other fragments did not significantly downregulate EEA1, as revealed through western blot. The effect of ARD10 expression was unclear because of its almost undetectable expression. Therefore, N + ARD25 was implicated as the active fragment for membrane vesiculation of early endosomes.

We then examined the effect of expression of ANKHD1 and its fragments on the total area and the number of EEA1 puncta in HeLa cells ([Figures S9](#mmc1){ref-type="supplementary-material"}A--S9D). The expression of N + ARD25 and ANKHD1 decreased the total area of EEA1 staining than those of other ANKHD1 fragments ([Figure S9](#mmc1){ref-type="supplementary-material"}C). ANKHD1 expression slightly decreased the number of EEA1 puncta, although the reduction in the number of EEA1 puncta upon expression of ANKHD1 fragments was not significant ([Figure S9](#mmc1){ref-type="supplementary-material"}D). Therefore the expression of ANKHD1 or its N + ARD25 fragment potentially decreases EEA1-positive organelles. In contrast, N + ARD25 expression did not affect the ER, mitochondria, and Golgi apparatus, as examined on the basis of changes in the total area of Calnexin, MitoTracker, and GM130 staining, respectively ([Figures S9](#mmc1){ref-type="supplementary-material"}E--S9J). The number of Golgi fragments remained unchanged upon N + ARD25 expression ([Figure S9](#mmc1){ref-type="supplementary-material"}K).

Furthermore, vesiculation of liposomes comprising PC, PE, and PS at a weight ratio of 6:3:1 by these ANKHD1 fragments was examined *in vitro*, using the ANKHD1 fragments expressed and purified from *E. coli*. This phospholipid composition is similar to that of early endosomes ([@bib7], [@bib22]). In liposome sedimentation assays, the N + ARD25 fragment showed greater vesiculation potential than the ARD25, N + ARD15, and ARD10 fragments at a 250 nM protein concentration ([Figures 5](#fig5){ref-type="fig"}D and 5E). Transmission electron microscopy revealed that N + ARD15 did not vesiculate liposomes; however, ARD10 and ARD25 deformed the membrane into tubes and N + ARD25 vesiculates liposomes into small vesicles in such a condition ([Figure 5](#fig5){ref-type="fig"}F). Interestingly, ARD10 displayed a greater vesiculation potential than N + ARD15 at a 1 μM protein concentration ([Figures 5](#fig5){ref-type="fig"}G and 5H).

As the membrane-deforming proteins often form dimers and oligomers, the assembly of ANKHD1 was examined via a chemical cross-linking assay with or without liposomes. N + ARD15, N + ARD25, and ARD25 were cross-linked via bis-*N*-succinimidyl-(pentaethylene glycol) ester (BS(PEG)5) ([Figure 5](#fig5){ref-type="fig"}I). N + ARD25 was more efficiently cross-linked than ARD25 ([Figure 5](#fig5){ref-type="fig"}I). In contrast, ARD10 did not exhibit clear dimer or oligomer bands after the cross-linking reaction ([Figure 5](#fig5){ref-type="fig"}I). Cross-linking occurred in the presence and absence of liposomes. These results suggest the involvement of N + ARD15 in dimer formation, which enabled the efficient vesiculation by N + ARD25 through ARD10.

Vesiculation Ability of ANKHD1 Results from the Amphipathic Helix and Electrostatic Interactions {#sec2.6}
------------------------------------------------------------------------------------------------

At the deformation sites of endosomes, especially for the recycling endosomes, PS is considered to be enriched because of the presence of lipid flippase ([@bib4], [@bib26], [@bib53], [@bib60]). Therefore, we also examined the vesiculation of liposomes comprising PC, PE, and PS at a weight ratio of 4:3:3. Similar to liposomes comprising PC, PE, and PS at a weight ratio of 6:3:1, the N + ARD25 fragment displayed the most efficient vesiculation ([Figure 6](#fig6){ref-type="fig"}A). Vesiculation of these liposomes depended on the concentration of the N + ARD25 protein ([Figure S10](#mmc1){ref-type="supplementary-material"}). We then filtered the liposomes to reduce the size of liposomes larger than 800 nm. The filtered liposomes were vesiculated in a manner similar to the non-filtered liposomes, suggesting that the large liposome diameter was not required for vesiculation ([Figure S10](#mmc1){ref-type="supplementary-material"}). We then examined the binding of these fragments by increasing the centrifugation speed used for the liposome sedimentation assay. The binding of the N + ARD25, ARD10, and ARD25 fragments to these liposomes were observed, whereas ARD15 did not bind to liposomes, indicating that ANKHD1 interacts with liposomes through ARD10 ([Figure 6](#fig6){ref-type="fig"}B).Figure 6Vesiculation Ability of ANKHD1 Caused by Amphipathic Helix and Electrostatic Interaction(A) Vesiculation by liposome sedimentation assay for N + ARD15, ARD10, N + ARD25, and ARD25 at 250 nM using ultracentrifugation at 109,000 × *g*. The lipid composition of the liposomes was PC:PE:PS:rhodamine-PE at a weight ratio of 4:3:3:0.02. The percentage of the rhodamine-PE fluorescence in the supernatant is shown. Data represent the mean of three independent experiments. See also [Figure S10](#mmc1){ref-type="supplementary-material"}.(B) Protein binding by liposome sedimentation assay for N + ARD15, ARD10, N + ARD25, and ARD25 at 250 nM using ultracentrifugation at 245,000 × *g*, where most of the liposomes were pelleted. The lipid composition of the liposomes was PC:PE:PS:rhodamine-PE at a weight ratio of 4:3:3:0.02. The percentage of the protein in the pellet is shown. Data represent the mean of three independent experiments.(C) Illustration of the mutations (K1323E-K1324E and R1357E-K1358E) and amphipathic helix (1400--1415 aa) of N + ARD25 (ANKHD1-1-1587 aa). The wheel diagram of the predicted amphipathic helix (1400--1415 aa residues) in ANKHD1 by HeliQuest is also shown. The hydrophobic moment indicates amphiphilicity of a helix. See also [Figure S11](#mmc1){ref-type="supplementary-material"}.(D and E) Vesiculation by liposome sedimentation assay for N + ARD25 and its mutations in which basic amino acids were substituted into acidic amino acids (K1323E-K1324E or R1357E-K1358E) or deletion of the amphipathic helix (Δ 1,400--1,415 aa) at 250 nM (D) and 150 nM (E). The lipid composition of liposomes was PC:PE:PS:rhodamine-PE at a weight ratio of 4:3:3:0.02. The percentage of rhodamine-PE fluorescence in the supernatant is also shown. Data represent the mean of three (D) or four (E) independent experiments.(F) Vesiculation by liposome sedimentation assay for N + ARD25 and its mutations with K1323E-K1324E-R1357E-K1358E (4E) or K1323E-K1324E-R1357E-K1358E+Δ 1,400--1,415 aa (4E+ΔAH) at 250 nM. The lipid composition of the liposomes was PC:PE:PS:rhodamine-PE at a weight ratio of 4:3:3:0.02. The percentage of rhodamine-PE fluorescence in the supernatant is shown. Data represent the mean of four independent experiments.(G) Electron micrographs of liposomes after incubation with N + ARD25 or 4E+ΔAH at 250 nM for 20 min. The liposome composition was PC:PE:PS at a weight ratio of 4:3:3. Scale bars, 100 nm.All error bars represent SE. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001. Statistical significance was determined with the Student\'s t test. ns, not significant.

We attempted to examine the contribution of electrostatic interactions between the positively charged amino acid residues of ANKHD1 and the negatively charged lipids with respect to the vesiculation ability. Sequence alignments of the ANKs in ANKHD1 showed that the 10 ANKs contain more frequent positively charged amino acid residues at positions 1 and 2 in the ANK compared with the 15 ANKs ([Figure S11](#mmc1){ref-type="supplementary-material"}A). Thereafter the predicted structure of the 10 ANKs via the Phyre2 program ([@bib20]) was used to detect the positively charged surface ([Figures S11](#mmc1){ref-type="supplementary-material"}B and S11C), which resulted in N + ARD25 fragments with K1323E-K1324E and R1357E-K1358E mutations ([Figure 6](#fig6){ref-type="fig"}C). At protein concentrations of 250 and 150 nM, the N + ARD25 K1323E-K1324E and R1357E-K1358E mutants displayed decreased vesiculation potential compared with N + ARD25 ([Figures 6](#fig6){ref-type="fig"}D and 6E). These results suggest that ANKHD1-mediated membrane scission involves electrostatic interactions between the membrane and proteins.

The hydrophobic moment indicates the amphiphilicity of a potential α-helix. Determination of the hydrophobic moment using HeliQuest ([@bib11]) indicated the presence of a potential amphipathic helix at 1400--1415 aa ([Figures 6](#fig6){ref-type="fig"}C and [S11](#mmc1){ref-type="supplementary-material"}D). At protein concentrations of 250 and 150 nM, the N + ARD25 mutant with the deletion of 1400--1415 aa (Δ1400--1415 aa) displayed a decreased vesiculation ability compared with that of N + ARD25 ([Figures 6](#fig6){ref-type="fig"}D and 6E).

Furthermore, we generated N + ARD25 with K1323E-K1324E + R1357E-K1358E mutations (4E) and K1323E-K1324E + R1357E-K1358E + Δ1400-1415 aa mutations (4E+ΔAH). In liposome sedimentation assays, the 4E+ΔAH mutant drastically decreased vesiculation compared with N + ARD25 and the 4E mutant via liposome sedimentation ([Figure 6](#fig6){ref-type="fig"}F). We visualized these liposomes via electron microscopy. Vesiculated liposomes were observed after incubation with the N + ARD25 fragment, but not with the 4E+ΔAH mutant ([Figure 6](#fig6){ref-type="fig"}G). Therefore the combination of mutations in the positively charged amino acid residues and the deletion of the amphipathic helix further reduced the vesiculation ability, indicating that both electrostatic interactions and the amphipathic helix contributed to membrane vesiculation, suggesting that ANKHD1 can cause membrane deformation and vesiculation in a manner similar to that of BAR domain proteins ([Figure S11](#mmc1){ref-type="supplementary-material"}E).

ANKHD1 Regulates the Size and Number of Early Endosomes through Membrane Vesiculation {#sec2.7}
-------------------------------------------------------------------------------------

To investigate the role of vesiculation of ANKHD1 in early endosomal regulation, we expressed the siRNA-resistant ANKHD1-EGFP and its 4E+ΔAH mutant in ANKHD1 siRNA-treated cells at levels similar to those of endogenous ANKHD1 ([Figure 7](#fig7){ref-type="fig"}A). In ANKHD1-depleted cells, the amount, total area, and the number of EEA1 was greater than that of EEA1 in control cells ([Figures 7](#fig7){ref-type="fig"}A--7E). The expression of ANKHD1-EGFP, but not 4E+ΔAH-EGFP, restored the amount of EEA1 protein, as well as the total area and the number of EEA1-positive puncta in ANKHD1-depleted cells to physiological levels in the control cells ([Figures 7](#fig7){ref-type="fig"}A--7E). To examine the effect of ANKHD1-mediated vesiculation on EEA1-positive early endosome, we analyzed the size distribution of EEA1-positive puncta per cell in these cells. The number of EEA1-positive puncta increased in all four size ranges upon treatment with ANKHD1 siRNA (\<0.1, 0.1--0.2, 0.2--0.4, and 0.4\< μm^2^) ([Figure 7](#fig7){ref-type="fig"}F). The expression of ANKHD1-EGFP restored the number of EEA1-positive puncta in all four size ranges to those in control cells, whereas the expression of its 4E+ΔAH mutant did not restore the number of EEA1-positive puncta in all four size ranges ([Figure 7](#fig7){ref-type="fig"}F). The average area of the EEA1-positive puncta per cell was largely unaltered ([Figure 7](#fig7){ref-type="fig"}G). These results indicate that the membrane vesiculation ability of ANKHD1 is essential for vesiculation of EEA1-positive early endosomes.Figure 7ANKHD1 Regulates the Size and Number of EEA1-Positive Early Endosomes by Vesiculation Ability(A) Amounts of endogenous ANKHD1, endogenous EEA1, and expressed ANKHD1 in HeLa cells transfected with control siRNA + EGFP, ANKHD1 siRNA + EGFP, ANKHD1 siRNA + ANKHD1-EGFP, or ANKHD1 siRNA + ANKHD1-EGFP with 4E+ΔAH (4E+ΔAH-EGFP) for rescue experiments by western blot.(B) Quantification of EEA1 in (A). Data represent the mean of four independent experiments.(C) Confocal microscopic images of endogenous EEA1 for the rescue experiments as in (A). Scale bars, 10 μm.(D--G) The total area (D) and the number (E), the size distribution (F), and the average area (G) of EEA1 puncta per cell in (C) were measured using ImageJ software. Data represent the mean of 27, 27, 25, and 25 cells from three independent experiments for control siRNA + EGFP, ANKHD1 siRNA + EGFP, ANKHD1 siRNA + ANKHD1-EGFP, and ANKHD1 siRNA + 4E+ΔAH-EGFP, respectively.All error bars represent SE. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001. Statistical significance was determined with the Student\'s t test. ns, not significant.

On expressing siRNA-resistant ANKHD1 and its 4E+ΔAH mutant in ANKHD1 siRNA-treated cells to levels similar to those of endogenous ANKHD1 in Rab5Q79L-expressing cells ([Figure 8](#fig8){ref-type="fig"}A), ANKHD1 expression adequately restored the number and average area of Rab5Q79L-positive early endosomes; however, the 4E+ΔAH mutant could not restore those in Rab5Q79L-positive early endosomes, which remained enlarged ([Figures 8](#fig8){ref-type="fig"}B--8D). These results suggest that ANKHD1 regulates early endosome through vesiculation.Figure 8ANKHD1 Regulates the Size and Number of Rab5-Positive Organelles through Vesiculation Ability(A) Amounts of endogenous ANKHD1 and expressed ANKHD1 in HeLa cells transfected with control siRNA + Venus×3, ANKHD1 siRNA + Venus×3, ANKHD1 siRNA + ANKHD1- Venus×3, or ANKHD1 siRNA + ANKHD1- Venus×3 with 4E+ΔAH (4E+ΔAH- Venus×3) for rescue experiments by western blot.(B) Confocal microscopic images of expressed mCherry-Rab5Q79L in HeLa cells transfected with control siRNA + Venus×3 + mCherry-Rab5Q79L, ANKHD1 siRNA + Venus×3 + mCherry-Rab5Q79L, ANKHD1 siRNA + ANKHD1- Venus×3 + mCherry-Rab5Q79L, or ANKHD1 siRNA + 4E+ΔAH- Venus×3 + mCherry-Rab5Q79L for rescue experiments. Scale bars, 10 μm.(C and D) Quantification of the number (C) and average area (D) of mCherry-Rab5Q79L puncta per cell in (B). Data represent the mean of 23, 19, 16, and 19 cells from three independent experiments for control siRNA + Venus×3, ANKHD1 siRNA + Venus×3, ANKHD1 siRNA + ANKHD1- Venus×3, and ANKHD1 siRNA + 4E+ΔAH- Venus×3, respectively.All error bars represent SE. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001. Statistical significance was determined using the Student\'s t test. ns, not significant.

Discussion {#sec3}
==========

ANKHD1 contains 25 ANKs, potentially divisible into a group containing the first 15 ANKs and a group containing the last 10 ANKs. We observed that ANKHD1 dimerization occurred through the N-terminal region containing the 15 ANKs. Membrane vesiculation occurred with the 10 ANKs, which was considered to be enhanced by the dimerization among the first 15 ANKs. ARDs often assume curved conformations, as in case of Ankyrin-R, which has 24 ANKs ([@bib55]). The predicted structure of the latter 10 ANKs suggested abundance of positively charged amino acid residues in its protein surface, which is similar to the lipid-binding surface of the BAR domain. Furthermore, an amphipathic helix was adjacent to the latter 10 ANKs. Some BAR domains capable of membrane scission contain amphipathic helices ([@bib3]). Therefore, it is reasonable that ANKHD1 has the potential for membrane deformation and vesiculation.

Our *in vitro* studies suggest that the ARD of ANKHD1 can produce liposome tubules and vesicles. The mutations with K1323E-K1324E or R1357E-K1358E, which were speculated to reduce the interaction with charged lipid PS, decreased the vesiculation ability. Deletion of the amphipathic helix was speculated to diminish the insertion of the amphipathic helix into the membrane, thereby decreasing membrane scission.

Membrane scission for vesiculation appears independent of ATP or GTP hydrolysis, at least *in vitro*. There are several examples of membrane vesiculation by proteins without ATP or GTP *in vitro*. The BAR domain superfamily of proteins with amphipathic helices, including endophilin, vesiculates liposomes *in vitro* ([@bib3], [@bib10]), probably through mechanical force ([@bib48]). ANKHD1 might vesiculate the membrane in combination with mechanical forces, including the force resulting from the flow of the medium *in vitro* and by intracellular motor proteins.

In ANKHD1-knockdown cells, EEA1-positive early endosomes were increased, as evident from the amount of the EEA1 marker protein. However, the endosomal localization of ANKHD1 was unclear. If ANKHD1 mediated membrane scission, it is possible that endosomal ANKHD1 localization was limited. Partial colocalization of proteins with vesiculation potential to target organelles was reported for dynamin and ESCRT ([@bib12], [@bib24], [@bib46]).

Early endosomes are associated with the continuous fusion of endocytic vesicles. The Rab5-positive endosomal tubules are generated after homotypic fusion of early endosomes ([@bib49]). Knockdown of ANKHD1 enlarged the Rab5Q79L-positive endosomes, indicating that ANKHD1 mediates its activity with activated Rab5. As the constitutive activation of Rab5 increases Rab5-positive endosomes, a further increase in endosomes induced by ANKHD1 downregulation indicated that ANKHD1 negatively regulates fusion-mediated enlargement of early endosomes.

Early endosomes are vesiculated, and the vesicles are transported to the plasma membrane, *trans*-Golgi, and recycling endosomes. Rab5 is not localized to the budding compartment of early endosomes for any of these three components ([@bib2], [@bib13], [@bib32], [@bib38], [@bib50]). In addition to such trafficking, early endosomes with Rab5 are converted into late endosomes with Rab7, which then fuse to form lysosomes ([@bib43]). LysoTracker staining indicated that endosome maturation to late endosomes and lysosomes appeared unaffected because LysoTracker staining intensity was not significantly altered by ANKHD1 siRNA treatment ([Figure S8](#mmc1){ref-type="supplementary-material"}). Vesiculation of early endosomes by ANKHD1 is potentially involved in unknown trafficking pathways, which might be related to mitochondria owing to the downregulation of mitochondrial marker proteins ([Figures 2](#fig2){ref-type="fig"}K and 2L). Alternatively, because ANKHD1 did not perfectly colocalize with Rab5, vesicles generated by ANKHD1 are potentially involved in trafficking to recycling endosomes or plasma membrane, which contain a large amount of PS ([@bib4], [@bib26], [@bib53], [@bib60]).

Some studies have reported interactions between the early endosome and mitochondria. The Hippo pathway provides a connection between ANKHD1 and mitochondria. Upon activation of the Hippo pathway, ANKHD1 is transferred into the cytosol ([@bib45], [@bib47]). In *Drosophila*, the loss of Mask, the homolog of human ANKHD1, induces mitophagy, a type of autophagy specific to the clearance of damaged mitochondria ([@bib61]). We observed a reduction in the number of mitochondria in ANKHD1-depleted cells, which might have been induced by mitophagy. Concurrently, endocytic proteins regulate the size of mitochondria by an indirect association with mitochondrial fission ([@bib8]), suggesting a potential ANKHD1-dependent vesicle transport from endosomes to mitochondria. Endosomal motility is reportedly affected by the interactions of endosomes with mitochondria ([@bib5]), thus indicating the site of ANKHD1 activity. Nonetheless, detailed functional mechanisms of action of intracellular ANKHD1 warrant further investigation.

Limitations of the Study {#sec3.1}
------------------------

We showed that the ARD of ANKHD1 vesiculated the liposomes into small vesicles *in vitro*. However, we could not examine the *in vitro* vesiculation ability of the full-length ANKHD1 because we could not successfully express and purify the protein; however, we expressed the wild-type and the vesiculation-deficient mutant of the full-length ANKHD1 protein in ANKHD1-siRNA-treated cells, confirming the vesiculation ability of the full-length protein. Furthermore, we used the reconstituted liposomes, which might not have the same lipids of early endosome. We observed early endosomes by immunofluorescence staining using anti-EEA1 and anti-Rab5 antibodies, which might not perfectly indicate the early endosomes because of limits in the antibody staining including background staining. In further studies, observation of early endosome and other organelles in the control cells and the ANKHD1-depleted cells by electron microscopy will improve the understanding of the function of ANKHD1.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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